

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-12 (Cancelled)

13. (Currently Amended) A method for at least one of treatment of obesity, prevention of obesity, treatment of an overweight condition, prevention of an overweight condition, controlling body weight reduction, and prevention of body weight gain, comprising:

administering an effective amount of a fatty acid composition comprising at least one of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, or any combinations thereof, to at least one of a human and an animal, wherein the weight ratio of EPA:DHA in the fatty acid composition is 1:X, where X is greater than 1;

wherein the concentration of EPA ranges from 10% to 20% and the concentration of DHA ranges from 20% to 50%.

14. (Cancelled)

15. (Previously Presented) The method according to claim 13, wherein the EPA and DHA are present in the composition in an EPA:DHA ratio ranging no more than 1:8.

16. (Previously Presented) The method according to claim 13, wherein the fatty acids in the composition are present in at least one of esterified form, ethyl ester form, salt form and free acid form, and any combinations thereof.

17. (Previously Presented) The method according to claim 13, wherein the fatty acid composition comprises EPA and DHA in triglyceride form.

18. (Previously Presented) The method according to claim 13, wherein at least one of EPA and DHA is obtained from at least one of vegetable, microbial and animal origin.

19. (Previously Presented) The method according to claim 13, wherein at least a part of the EPA and/or DHA is obtained from a marine oil.

20. (Previously Presented) The method according to claim 13, wherein the composition is administered orally to the at least one of a human and an animal.

21. (Previously Presented) The method according to claim 13, wherein the treatment is carried out together with a reduced intake of calories for the at least one of a human and an animal.

22. (Previously Presented) The method according to claim 13, wherein said fatty acid composition is administered in a daily dosage that corresponds to at least 10% of the total lipid content of a daily diet for the at least one of a human and an animal.

Claims 23-36 (Cancelled)

37. (Currently Amended) A dietary product containing a fatty acid composition comprising at least one of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid

(DHA), or derivatives thereof, or any combinations thereof, for at least one of non-medical treatment of obesity, non-medical treatment of an overweight condition, prevention of obesity, prevention of an overweight condition, supporting and controlling body weight reduction, and prevention of body weight gain, wherein the weight ratio of EPA:DHA in the fatty acid composition is 1:X, where X is greater than 1;

wherein the concentration of EPA ranges from 10% to 20% and the concentration of DHA ranges from 20% to 50%.

38. (Cancelled)

39. (Previously Presented) The dietary product according to claim 37, wherein the DHA is the main active ingredient.

40. (Previously Presented) The dietary product according to claim 37, wherein the dietary product is at least one of a weight-watching product and a slimming product.

41. (Previously Presented) The dietary product according to claim 37, wherein the EPA and DHA are present in the composition in an EPA:DHA ratio no more than 1:8.

42. (Previously Presented) The dietary product according to claim 37, wherein at least one of EPA and DHA is obtained from at least one of vegetable, microbial and animal origin.

43. (Previously Presented) The dietary product according to claim 37, wherein the fatty acid composition is obtained from a marine oil.

44. (Previously Presented) The dietary product according to claim 37, wherein intake of the dietary product is combined with at least one of a reduced intake of calories for a human and physical activity.

45. (Previously Presented) The dietary product according to claim 37, wherein said fatty acid composition is administered in a daily dosage that corresponds to at least 10 % of the total lipid content of a daily diet for at least one of a human and an animal.

46. (Previously Presented) The dietary product according to claim 37, wherein the dietary product is at least one of a bar, a snack, and a beverage.

47. (Cancelled)

48. (Cancelled)

49. (Currently Amended) A method for supplementing a dietary product comprising:

adding a fatty acid composition comprising at least one of (all-Z omega-3)5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, or any combinations thereof, to supplement the dietary product for at least one of prevention of body weight gain and controlling and supporting weight reduction in a human, wherein the weight ratio of EPA:DHA in the fatty acid composition is 1:X, where X is larger than 1;

wherein the concentration of EPA ranges from 10% to 20% and the concentration of DHA ranges from 20% to 50%.

50. (Cancelled)

51. (Previously Presented) The method according to claim 49, wherein the fatty acid composition is present in at least one of liquid form and as an emulsion, being incorporated in said dietary product.

52. (Previously Presented) The method according to claim 1, wherein said fatty acid composition is chosen from a supplement, a food supplement, and a nutritional product.

53. (Previously Presented) A method for at least one of treatment of obesity, prevention of obesity, treatment of an overweight condition, prevention of an overweight condition, controlling body weight reduction, and prevention of body weight gain, comprising:

administering an effective amount of a fatty acid composition comprising at least one of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA), or derivatives thereof, and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA), or derivatives thereof, or any combinations thereof, to at least one of a human and an animal, wherein the concentration of EPA ranges from 10% to 20% and the concentration of DHA ranges from 20% to 50% and the concentration of DHA is greater than the concentration of EPA.

54. (Previously Presented) The method according to claim 53, wherein the concentration of EPA is 10% and the concentration of DHA is 50%.

55. (Previously Presented) The method according to claim 53, wherein the concentration of EPA is 20% and the concentration of DHA is 50%.

56. (Cancelled)

57. (Currently Amended) The method according to claim 13 [[56]], wherein the concentration of EP is 10% and the concentration of DHA is 50%.

58. (Currently Amended) The method according to claim 13 [[56]], wherein the concentration of EPA is 20% and the concentration of DHA is 50%.

59. (Cancelled)

60. (Currently Amended) The method according to claim 37 [[59]], wherein the concentration of EP is 10% and the concentration of DHA is 50%.

61. (Currently Amended) The method according to claim 37 [[59]], wherein the concentration of EPA is 20% and the concentration of DHA is 50%.